featured
Impact of Molecular Classification on Prognosis and Benefit From Adjuvant Therapy for High-Risk Endometrial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
J. Clin. Oncol 2020 Aug 04;[EPub Ahead of Print], A León-Castillo, SM de Boer, ME Powell, LR Mileshkin, HJ Mackay, A Leary, HW Nijman, N Singh, PM Pollock, P Bessette, A Fyles, C Haie-Meder, VTHBM Smit, RJ Edmondson, H Putter, HC Kitchener, EJ Crosbie, M de Bruyn, RA Nout, N Horeweg, CL Creutzberg, T BosseFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.